&nbsp;

CCO_SilentEnemyDigital-OjiCree.pdf

Sep 2022

Regimen

CISPGEMC(W)+DURV

Cancer Type:

Gastrointestinal,

Hepatobiliary / Liver / Bile Duct

Intent: Palliative

Funding:

New Drug Funding Program

Durvalumab - Locally Advanced Unresectable or Metastatic Biliary Tract Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph

Apr 2024

Regimen

CISPPEME+NIVL

Cancer Type:

Lung,

Non-Small Cell

Intent: Neoadjuvant

Funding:

New Drug Funding Program

Nivolumab - Neoadjuvant Treatment for Non-Small Cell Lung Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph

May 2024

Regimen

CISPVINO+NIVL

Cancer Type:

Lung,

Non-Small Cell

Intent: Neoadjuvant

Funding:

New Drug Funding Program

Nivolumab - Neoadjuvant Treatment for Non-Small Cell Lung Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph

May 2024

Regimen

CISPGEMC+NIVL

Cancer Type:

Lung,

Non-Small Cell

Intent: Neoadjuvant

Funding:

New Drug Funding Program

Nivolumab - Neoadjuvant Treatment for Non-Small Cell Lung Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph

May 2024

Guidelines and Advice

Hepatitis B Virus Screening and Management for Patients Receiving Systemic Treatment

Status: Current

Sep 2022

Document

CAR T-cell therapy for adult relapsedrefractory lymphoma (third or subsequent line).pdf

Oct 2022

Document

HCP_Should-my-patients-start-on-a-biosimilar.pdf

Nov 2022

Document

HCP_Should-I-switch-a-patient-to-a-biosimilar.pdf

Nov 2022

Document

HCP_Should-my-patients-start-on-a-biosimilar_FR.pdf

Nov 2022

Document

HCP_Should-I-switch-a-patient-to-a-biosimilar_FR.pdf

Nov 2022

Document